3330 Clinical benefits associated with durable response (DR) in patients (pts) with unresected stage IIIB/C/IV melanoma treated with talimogene laherparepvec (T-VEC) or GM-CSF in the randomized phase 3 OPTiM trial (NCT00769704). (September 2015) - Kaufman, H.L.; Andtbacka, R.H.I.; Collichio, F.A.; Wolf, M.; Li, A.; Shilkrut, M.; Murugappan, S.; Zhao, Z.; Puzanov, I.; Ross, M.